Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sagimet Biosciences Inc.SGMT · Entity 5273 | Chief Legal & Admin. Officer | July 20, 2026 | July 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sagimet Biosciences Inc.
Report date July 20, 2026 · Filed July 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series A Common StockSEC Table I · non-derivative | Direct | 224,414 |
Reported balance
After 2026-07-20 transaction · row 1
1 source rowRow 1 · 2026-07-20 · Sale · Disposed 10,545 · Balance 224,414 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $7.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $7.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 20, 2026 Filed Jul 22, 2026 20:05 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | SaleSeries A Common Stock | 10,545 | $7.76 | $81,832.36 |
DisclosureSEC source: 0001193125-26-312394 · ownership.xml · nonDerivative · entry 1 Rozek Elizabeth · CIK 0001975022 · Chief Legal & Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,414 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $7.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 28, 2026 Filed Jun 2, 2026 01:14 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001104659-26-069122 · tm2616578-2_4seq1.xml · derivative · entry 1 Rozek Elizabeth · CIK 0001975022 · Chief Legal & Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Series A Common Stock · 100,000 shares Expires 2036-05-27 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following May 28, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:43 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 88,000 | $0.00 Strike: $5.38 | $0.00 |
DisclosureSEC source: 0001104659-26-018196 · tm266959-4_4seq1.xml · derivative · entry 2 Rozek Elizabeth · CIK 0001975022 · Chief Legal & Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,000 Underlying: Series A Common Stock · 88,000 shares Expires 2036-02-18 F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:43 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantSeries A Common Stock | 44,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-018196 · tm266959-4_4seq1.xml · nonDerivative · entry 1 Rozek Elizabeth · CIK 0001975022 · Chief Legal & Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,959 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:05 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | SaleSeries A Common Stock | 2,622 | $5.36 | $14,054.44 |
DisclosureSEC source: 0001104659-26-014266 · tm266207-1_4seq1.xml · nonDerivative · entry 1 Rozek Elizabeth · CIK 0001975022 · Chief Legal & Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,959 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 21:43 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 13,367 | $0.00 Strike: $7.61 | $0.00 |
DisclosureSEC source: 0001104659-25-107806 · tm2530509-1_4seq1.xml · derivative · entry 2 Rozek Elizabeth · CIK 0001975022 · Chief Legal & Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,367 Underlying: Series A Common Stock · 13,367 shares Expires 2035-11-03 F2 · derivative.exercise_date: This option was granted in connection with the Reporting Person's promotion within the Company. The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following November 4, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 21:43 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantSeries A Common Stock | 9,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-107806 · tm2530509-1_4seq1.xml · nonDerivative · entry 1 Rozek Elizabeth · CIK 0001975022 · Chief Legal & Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,581 F1 · shares: Represents restricted stock units ("RSUs") granted in connection with the Reporting Person's promotion within the Company. Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following November 4, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 21, 2025 Filed Jul 23, 2025 20:14 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | SaleSeries A Common Stock | 10,780 | $9.13 | $98,470.99 |
DisclosureSEC source: 0001104659-25-070013 · tm2521574-1_4seq1.xml · nonDerivative · entry 1 Rozek Elizabeth · CIK 0001975022 · General Counsel and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,726 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:42 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 138,000 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001104659-25-010586 · tm255919-2_4seq1.xml · derivative · entry 2 Rozek Elizabeth · CIK 0001975022 · General Counsel and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,000 Underlying: Series A Common Stock · 138,000 shares Expires 2035-02-05 F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:42 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantSeries A Common Stock | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-010586 · tm255919-2_4seq1.xml · nonDerivative · entry 1 Rozek Elizabeth · CIK 0001975022 · General Counsel and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,506 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 19, 2024 Filed Jul 23, 2024 20:05 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | SaleSeries A Common Stock | 10,914 | $3.10 | $33,830.13 |
DisclosureSEC source: 0001104659-24-081891 · tm2420000d2_4seq1.xml · nonDerivative · entry 1 Rozek Elizabeth · CIK 0001975022 · General Counsel and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,506 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 21:25 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantSeries A Common Stock | 171,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-120377 · tm2331048-4_4seq1.xml · nonDerivative · entry 1 Rozek Elizabeth · CIK 0001975022 · General Counsel and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,420 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. 25% of the RSUs shall vest on July 18, 2024, with the remainder vesting in three equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:19 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 242,142 | $0.00 Strike: $13.51 | $0.00 |
DisclosureSEC source: 0001104659-23-082734 · tm2321276-21_4seq1.xml · derivative · entry 2 Rozek Elizabeth · CIK 0001975022 · General Counsel and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,142 Underlying: Series A Common Stock · 242,142 shares Expires 2033-04-19 F1 · timeliness: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on April 10, 2024, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:19 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 242,142 | $0.00 Strike: $13.51 | $0.00 |
DisclosureSEC source: 0001104659-23-082734 · tm2321276-21_4seq1.xml · derivative · entry 1 Rozek Elizabeth · CIK 0001975022 · General Counsel and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 242,142 shares Expires 2033-04-19 F1 · timeliness: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on April 10, 2024, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.